FDA/CDC
FDA/CDC
New buprenorphine formulation approved for medication-assisted treatment
Patients who are currently taking other buprenorphine formulations can be transitioned.
FDA/CDC
FDA clears first-ever neurostimulation device for opioid withdrawal symptoms
In one study, almost 90% of patients transitioned to medication-assisted treatment after 5 days of using the device.
Latest News
Adherence boon, or Big Brother loom?
Take our poll on the first drug approved in the United States with a digital ingestion tracking system.
FDA/CDC
FDA approves cariprazine for schizophrenia maintenance treatment
Approval is based on results of a 72-week double-blind, randomized study of three daily doses of the antipsychotic, compared with placebo.
FDA/CDC
FDA panels support two NDAs for buprenorphine subcutaneous injections
The panelists agree that subcutaneous formulations might help step the opioid epidemic.
FDA/CDC
Do not withhold opioid addiction drugs from patients taking benzodiazepines
The FDA says the benefits of combining MAT drugs with CNS depressants outweigh the risks.
FDA/CDC
FDA gives nod to first mobile app for substance use disorders
The reSET application is designed as an adjunct to outpatient therapy for patients with SUD aged 18 years and older.
FDA/CDC
FDA advisory committee rejects opioids in children’s cough syrup
Adolescents are the most at-risk population for opioid misuse.
FDA/CDC
Austedo approved for treatment of tardive dyskinesia
The drug was also approved in April 2017 to treat chorea associated with Huntington’s disease.
FDA/CDC
Extended-release amantadine approved for treatment of dyskinesia in Parkinson’s
This is the first FDA approval for a drug to treat levodopa therapy-related dyskinesia in patients with Parkinson’s disease.
FDA/CDC
Abilify Maintena OK’d by FDA for adults with bipolar I disorder
Approval of the long-acting injectable form of aripiprazole is based on a 52-week withdrawal trial in adults.